Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 6/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 3/20 | 0.47 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | HTR2C | P28335 | 5/20 | 0.36 |
| ▸ | HTR2B | P41595 | 4/20 | 0.36 |
| ▸ | HTR1A | P08908 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385717 | 1.00 | KMO (0.48) | KMODGAT1IRAK4FGFR1FGFR4 | |
| SCHEMBL1119861 | 0.89 | DGAT1 (0.47) | KMODGAT1HTR2AHTR2CNPC1 | |
| SCHEMBL2144138 | 0.84 | HTR2A (0.39) | KMODGAT1IRAK4HTR2AHTR2C | |
| SCHEMBL30485520 | 0.84 | HTR2A (0.39) | KMODGAT1IRAK4HTR2AHTR2C | |
| SCHEMBL30855572 | 0.84 | HTR2A (0.36) | KMODGAT1HTR2AHTR2CHTR2B | |
| SCHEMBL16437423 | 0.84 | KMO (0.50) | KMODGAT1HTR2AHTR2CHTR2B | |
| SCHEMBL2144622 | 0.84 | HTR2A (0.36) | KMODGAT1HTR2AHTR2CHTR2B | |
| SCHEMBL38656212 | 0.82 | NPC1 (0.43) | KMODGAT1NPC1RAB9AKMT2A | |
| SCHEMBL25345498 | 0.81 | DGAT1 (0.42) | DGAT1 | |
| SCHEMBL30032612 | 0.81 | DGAT1 (0.37) | KMODGAT1IRAK4HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250248998-A1 | LRRK2 Inhibitors | Brenig Therapeutics, Inc. | 2025-08-07 | — | — | US | disclosed |
| EP-4504722-A2 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4265608-A1 | BENZOHETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) | 2023-10-25 | — | — | EP | disclosed |
| WO-2023196720-A2 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-116262739-A | Nitrogen-containing aryl derivative regulator, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3694331-B1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2022-11-16 | — | — | EP | disclosed |
| US-11174248-B2 | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-108137510-B | Compound (I) | 葛兰素史密斯克莱知识产权发展有限公司 | 2021-07-20 | — | — | CN | disclosed |
| US-20210188818-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | MERCK SHARP & DOHME CORP. (US) | 2021-06-24 | — | — | US | disclosed |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| EP-1830853-B1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES | NOVARTIS AG (CH) | 2011-08-10 | — | — | EP | disclosed |
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2010-08-26 | — | — | US | disclosed |
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON, INC. (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ALCON, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250248998-A1 | LRRK2 Inhibitors | LRRK2, PARK7, PINK1 | KMO 1691/4885DGAT1 1666/4885IRAK4 2216/4885 |
| US-11174248-B2 | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof | LRRK2, BRSK2, CLK2 | KMO 2276/4885DGAT1 4169/4885IRAK4 303/4885 |
| US-10975081-B2 | Substituted fused pyrazole compounds and their use as LRRK2 inhibitors | LRRK2, PARK7, PINK1 | KMO 913/4885DGAT1 3394/4885IRAK4 1441/4885 |
| US-20100216777-A1 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | KMO 828/4885DGAT1 3516/4885IRAK4 2006/4885 |
| US-20080269249-A2 | AMINOPYRAZINE ANALOGS FOR TREATING GLAUCOMA AND OTHER RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOA | KMO 828/4885DGAT1 3516/4885IRAK4 2006/4885 |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | KMO 720/4885DGAT1 4426/4885IRAK4 11/4885 |
| US-20210188818-A1 | INDAZOLYL-SPIRO[2.3]HEXANE-CARBONITRILE DERIVATIVES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LRRK2, BRSK2, CLK2 | KMO 2276/4885DGAT1 4169/4885IRAK4 303/4885 |
| US-20060142307-A1 | Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases and conditions | ROCK2, ROCK1, RHOA | KMO 828/4885DGAT1 3516/4885IRAK4 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.